Suppr超能文献

成人预防疫苗与其他协同生活方式选择:是否是时候将这些辅助益处添加到 AS 整体管理清单中了?

Adult preventive vaccines with other synergistic lifestyle options: is it time to add these ancillary benefits to the overall AS management checklist?

机构信息

Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, 48109-5330, USA.

出版信息

World J Urol. 2022 Jan;40(1):43-49. doi: 10.1007/s00345-021-03709-2. Epub 2021 May 7.

Abstract

PURPOSE

To review the potential ancillary cardiovascular and other health impacts of compliance with general adult vaccination series in the prostate cancer active surveillance (AS) population. No previous review has been published in regard to this specific topic.

METHODS

Literature review of PubMed data up to December 2020 RESULTS: Compliance rates for adult vaccination are in the approximate anemic range of 25-50% with occasional higher rates of specific vaccines in the elderly population including annual influenza and pneumococcal prevention. Herpes zoster (HZ) and numerous other vaccine preventive illnesses are associated with an increased risk of cardiovascular events. Preliminary evidence suggests vaccine compliance could reduce overall morbidity and mortality, and adherence to heart healthy lifestyle changes and parameters could further improve vaccine efficacy and overall wellness. COVID-19 vaccine utilization and research should also continue to reinforce the direct and ancillary benefits of this entire preventive intervention category.

CONCLUSIONS

Multiple ancillary lifestyle change recommendations could be included in the AS criteria to potentially reduce morbidity and mortality in this population, and perhaps the most unsung intervention is to improve the inadequate rates of general adult vaccination compliance and other heart healthy behavioral changes that impact their efficacy. Heart health, prostate health, and immune system health are closely interlinked.

摘要

目的

回顾前列腺癌主动监测(AS)人群中遵循成人常规疫苗接种系列的潜在辅助心血管和其他健康影响。针对这一特定主题,之前没有发表过相关综述。

方法

对截至 2020 年 12 月的 PubMed 数据进行文献回顾。

结果

成人疫苗接种的依从率约为 25%-50%,偶尔老年人的某些疫苗接种率较高,包括每年接种流感和肺炎球菌预防疫苗。带状疱疹(HZ)和许多其他疫苗预防疾病与心血管事件风险增加有关。初步证据表明,疫苗接种可降低整体发病率和死亡率,坚持心脏健康的生活方式改变和参数可进一步提高疫苗的疗效和整体健康水平。COVID-19 疫苗的使用和研究也应继续加强这一整个预防干预类别的直接和辅助益处。

结论

可以在 AS 标准中纳入多种辅助生活方式改变建议,以降低该人群的发病率和死亡率,也许最不为人知的干预措施是提高成人常规疫苗接种依从率和其他影响疫苗疗效的心脏健康行为改变的不足率。心脏健康、前列腺健康和免疫系统健康密切相关。

相似文献

3
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
MMWR Surveill Summ. 2016 Feb 5;65(1):1-36. doi: 10.15585/mmwr.ss6501a1.
5
Vaccination among Medicare-fee-for service beneficiaries: Characteristics and predictors of vaccine receipt, 2014-2017.
Vaccine. 2019 Feb 21;37(9):1194-1201. doi: 10.1016/j.vaccine.2019.01.010. Epub 2019 Jan 22.
6
Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
Vaccine. 2021 Jun 11;39(26):3520-3527. doi: 10.1016/j.vaccine.2021.04.062. Epub 2021 May 20.
8
Challenges in adult vaccination.
Ann Med. 2018 May;50(3):181-192. doi: 10.1080/07853890.2017.1417632. Epub 2018 Jan 16.

引用本文的文献

1
Rapid Lifestyle Recommendations to Improve Urologic, Heart and Overall Health.
Curr Urol Rep. 2024 Oct 8;26(1):10. doi: 10.1007/s11934-024-01246-0.

本文引用的文献

1
Prevention of Hepatitis B Virus Infection and Liver Cancer.
Recent Results Cancer Res. 2021;217:71-90. doi: 10.1007/978-3-030-57362-1_4.
2
Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection.
Front Immunol. 2020 Oct 22;11:570681. doi: 10.3389/fimmu.2020.570681. eCollection 2020.
4
Prospective Observational Study of a Racially Diverse Group of Men on Active Surveillance for Prostate Cancer.
Urology. 2021 Feb;148:203-210. doi: 10.1016/j.urology.2020.09.044. Epub 2020 Nov 7.
6
Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study.
Nutr Cancer. 2021;73(11-12):2538-2545. doi: 10.1080/01635581.2020.1841250. Epub 2020 Nov 5.
9
Association Between the Risk for Cardiovascular Events and Antiviral Treatment for Herpes Zoster.
Clin Infect Dis. 2021 Sep 7;73(5):758-764. doi: 10.1093/cid/ciaa1384.
10
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验